Posted by Michael Wonder on 23 Nov 2016
Belsomra finally approved by TGA
23 November 2016 - The TGA has approved MSD's orexin receptor antagonist.
The TGA approved Belsomra on 16 November 2016 for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance.
The TGA rejected MSD's initial submission for suvorexant on 5 September 2014.
